Centrum für Hämatologie und Onkologie Bethanien

Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer. (2022) Fehm TN, Welslau M, Mueller V, Lueftner D, Schuetz F, Fasching P, Janni W, et al. Journal article, Review article Treatment-Free Remission in Real-World Chronic Myeloid Leukemia Patients: Insights from German Hematology Practices (2022) Dengler J, Tesch H, Jentsch-Ullrich K, Gerhardt A, Schulte C, Lipke J, Loewe G, Kiani A Journal article Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT (2022) Engler T, Fasching P, Lueftner D, Hartkopf AD, Mueller V, Kolberg HC, Hadji P, et al. Journal article Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2021) Marmé F, Solbach C, Michel L, Schneeweiss A, Blohmer JU, Huober J, Fasching P, et al. Journal article Everolimus eluting bioresorbable vascular scaffolds in patients with acute coronary syndromes: Two-year results from the German-Austrian ABSORB registry (2021) Tröbs M, Achenbach S, Nef HM, Gori T, Naber C, Neumann T, Richardt G, et al. Journal article Update Breast Cancer 2021 Part 2-Advanced Stages, Long-Term Consequences and Biomarkers (2021) Ditsch N, Stickeler E, Behrens A, Belleville E, Fasching P, Fehm TN, Hartkopf AD, et al. Journal article, Review article Update Breast Cancer 2021 Part 1-Prevention and Early Stages (2021) Stickeler E, Aktas B, Behrens A, Belleville E, Ditsch N, Fasching P, Fehm TN, et al. Journal article, Review article Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy (2021) Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lübbe K, et al. Journal article Ribecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole: Final results (2021) Reinisch M, Nusch A, Decker T, Hartkopf A, Heinrich BJ, Kurbacher CM, Fuchs R, et al. Conference contribution Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer (2021) Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, et al. Journal article